EXACT THERAPEUTICS ANNOUNCES CLINICAL TRIAL UPDATE
OSLO/LONDON, MAY 28th 2021
EXACT THERAPEUTICS AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today provided an update regarding the ongoing phase I ACTIVATE study.
Enrolment of patients in the study at the Royal Marsden Hospital in London has been adversely impacted through the Covid-19 pandemic period. There have been seven patients enrolled in the study with five patients’ data evaluable to date. A number of valuable and encouraging insights have been gained from this first cohort of treated patients, particularly with respect to application of ultrasound.
In addition, as the organisation has expanded with appointment of experienced senior executives, focus has increased on improving quality management and internal governance processes. As a consequence, robust internal governance processes have been developed and implemented.
In parallel, a protocol amendment is planned with a consequent impact on patient enrolment, which is anticipated to restart in Q4 2021.
This additional foundational work will provide a strong platform to evaluate the exciting potential of Acoustic Cluster Therapy in oncology and other therapeutic segments.
For more information contact:
EXACT Therapeutics
Dr Rafiq Hasan, CEO
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Manel Mateus
Tel: +44 (0) 203 922 1906
Email: Exact@optimumcomms.com
About EXACT-Tx
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com
About ACT®
ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
Initial focus of the company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.